Clarus, Cadre, iRhythm Stocks Hit Year Lows: Analysis and Investment Outlook - News and Statistics
A recent analysis from StockStory highlights three stocks, Clarus (NASDAQ:CLAR), Cadre (NYSE:CDRE), and iRhythm Technologies (NASDAQ:IRTC), that have reached one-year lows, prompting investors to consider their future. Clarus is identified as a "sell" due to stagnant sales, cash-burning tendencies, and diminishing returns on capital. Conversely, Cadre and iRhythm Technologies are marked as "stocks to watch" due to their strong revenue growth, improving profitability, and promising market expansion.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into iRhythm Technologies, Inc. (IRTC) concerning potential corporate wrongdoing by its officers and directors. The firm encourages shareholders who purchased iRhythm securities before January 11, 2022, and still hold them, to join the investigation. This investigation aims to restore investor capital and ensure corporate accountability.
iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains
iRhythm Technologies is experiencing significant business momentum, driven by a favorable Medicare coverage update, strong Q1 growth, and advancements in product and margin initiatives. The company highlights its core Zio Monitor business as a primary growth driver and anticipates a Q1 2027 launch for Zio MCT. iRhythm also emphasizes the role of AI in driving efficiency and margin improvements, aiming for 15% adjusted EBITDA margin and 73% gross margin by 2027.
iRhythm Technologies Touts Medicare Win, Zio Growth and AI-Driven Margin Gains
iRhythm Technologies reported strong Q1 2026 results, driven by favorable Medicare coverage, robust Zio Monitor growth, and improved profitability through automation and AI. The company reaffirmed its plans to launch Zio MCT in H1 2027 and highlighted AI as an efficiency driver for scan time and cost reductions. Management reiterated long-term targets of 15% adjusted EBITDA margin and 73% gross margin by 2027, alongside growing international momentum.
iRhythm Technologies stock hits 52-week low at $112.29
iRhythm Technologies (IRTC) stock has fallen to a new 52-week low of $112.29, declining 33% in six months and 36% year-to-date. Despite recent revenue beats and raised guidance, the company faces market pressures, though analysts anticipate profitability this year with significant upside potential.
Bessemer Group Inc. Decreases Position in iRhythm Technologies $IRTC
Bessemer Group Inc. reduced its stake in iRhythm Technologies (NASDAQ:IRTC) by 25.9% in the fourth quarter of 2025, selling 112,251 shares and holding 321,984 shares valued at $57.1 million. Despite this, other institutions like Royal Bank of Canada and Goldman Sachs increased their positions. iRhythm Technologies reported better-than-expected quarterly EPS of ($0.35) and a 25.6% year-over-year revenue increase to $199.39 million, leading to a consensus "Moderate Buy" rating with a target price of $193.38.
(IRTC) as a Liquidity Pulse for Institutional Tactics
This article provides an in-depth analysis of iRhythm Technologies Inc. (NASDAQ: IRTC) using AI models to suggest trading strategies. It highlights weak sentiment across all horizons, supporting a short bias, and outlines specific position, momentum, and risk-hedging strategies with entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, identifying support and resistance levels.
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) on behalf of investors who purchased securities before January 11, 2022, and continue to hold them. The investigation focuses on whether the company and its officers engaged in corporate wrongdoing. Shareholders are encouraged to contact the law firm to assist with the investigation at no cost to them.
UBS Group AG Has $27.19 Million Stock Position in iRhythm Technologies $IRTC
UBS Group AG significantly increased its stake in iRhythm Technologies (NASDAQ:IRTC) by 190.3% in the fourth quarter, reaching 153,218 shares valued at $27.2 million. This comes despite recent insider sales by the company's CEO and EVP. iRhythm Technologies reported better-than-expected quarterly results, with EPS of -$0.35 and revenue of $199.39 million, while analysts maintain a "Moderate Buy" rating with a consensus price target of $193.38.
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) for alleged corporate wrongdoing. The firm encourages investors who purchased iRhythm securities before January 11, 2022, and still hold them, to join the investigation. This class action representation is on a contingency fee basis.
IRTC SEC Filings - iRhythm Holdings, Inc 10-K, 10-Q, 8-K Forms
This page provides access to iRhythm Holdings, Inc. (IRTC) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms. It highlights recent filings with AI-powered summaries detailing financial performance, insider transactions, ownership changes, and corporate structure adjustments. The platform aims to help investors track iRhythm's financial health, risk factors, and governance through regulatory disclosures.
IRTC SEC Filings - iRhythm Holdings, Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for iRhythm Holdings (IRTC) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider trading forms (Form 4). It details how investors can access these regulatory documents, which include financial performance, risk factors, and corporate governance. The platform also offers AI-powered summaries to help users understand key points and identify major changes in financial condition or insider transactions.
IRTC SEC Filings - iRhythm Holdings, Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of iRhythm Holdings (IRTC) SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading forms. It highlights recent filings and uses AI-powered summaries to explain key points and analyze financial performance, risk factors, and corporate events. The platform aims to assist investors and analysts in understanding iRhythm's digital cardiac monitoring business and governance.
PANDA Trial Completion Puts iRhythm’s Pediatric Growth Story in Focus
iRhythm Technologies (IRTC) has announced the completion of its PANDA study, which evaluated the Zio monitor's effectiveness in pediatric patients requiring heart rhythm checks. The study aimed to assess the monitor's ability to maintain a strong signal over a 14-day wear period in children. This milestone is significant for IRTC's growth beyond adult monitoring and could expand its market in pediatric syncope, congenital heart disease, and arrhythmias.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into iRhythm Technologies, Inc. (IRTC) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased iRhythm securities before January 11, 2022, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC represents investors in class actions on a contingency fee basis and seeks to recover investor capital while ensuring corporate accountability.
iRhythm Holdings CTO Lawrence Lee sells $122,491 in stock
iRhythm Holdings CTO Lawrence Lee sold 1,014 shares of company stock worth $122,491 to cover tax obligations. The sale occurred while the stock, trading near its 52-week low and down 33% year-to-date, is considered overvalued by InvestingPro analysis despite the company's $3.86 billion market cap. Analysts have issued mixed updates on iRhythm Technologies, with some raising and others lowering price targets, following its Q1 2026 revenue of $199 million, which surpassed expectations.
IRTC SEC Filings - iRhythm Holdings, Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for iRhythm Holdings, Inc. (IRTC) SEC filings, including annual reports (10-K), quarterly reports (10-Q), and material event reports (8-K), along with insider trading forms. Stock Titan offers access to these regulatory documents, enhanced with AI-powered summaries and sentiment analysis to help investors understand key financial performance, risk factors, and corporate governance for the digital health care company focused on cardiac monitoring. Recent filings cover topics such as financial results, investor presentations, and proposed stock sales.
iRhythm Holdings CTO Lawrence Lee sells $122,491 in stock
Lawrence Brian Lee, CTO of iRhythm Holdings, sold 1,014 shares of company stock for $122,491 to cover tax obligations related to Restricted Stock Units. This transaction occurred as IRTC stock trades near its 52-week low and is considered overvalued by InvestingPro analysis, despite the company's recent strong Q1 2026 revenue performance. Analyst opinions vary on IRTC's valuation, though overall sentiment for its growth potential remains optimistic.
Wells Fargo & Company Has Lowered Expectations for iRhythm Technologies (NASDAQ:IRTC) Stock Price
Wells Fargo & Company has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) from $200 to $180, while maintaining an "overweight" rating, implying a potential 51% upside. This adjustment follows iRhythm's Q1 results, which surpassed EPS and revenue estimates but still showed the company as unprofitable, leading to a 7.8% stock drop. Despite mixed analyst views, the general sentiment remains positive, with a "Moderate Buy" consensus and an average price target of $202.23.
Citi Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Raises Target Price to $157
Citi has reiterated its Buy rating on IRhythm Technologies (IRTC.US) and increased its target price for the stock to $157. This indicates continued confidence in the company's performance and future prospects from the analytical firm.
IRTC SEC Filings - iRhythm Holdings, Inc 10-K, 10-Q, 8-K Forms
This page provides access to iRhythm Holdings, Inc. (IRTC) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It aims to be a comprehensive resource for investors, offering official regulatory documents and AI-powered summaries to help understand financial performance, risk factors, governance, and material corporate events related to the company's cardiac monitoring business. Recent filings cover topics such as initial statements of beneficial ownership, material events, insider trading activities, and amendments to executive policies.
IRhythm Technologies Price Target Raised to $255.00/Share From $254.00 by Needham
Needham has raised its price target for iRhythm Technologies (NASDAQ: IRTC) to $255.00 per share, an increase from the previous target of $254.00. The firm maintained a "Buy" rating on the medical device company's stock.
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) for alleged corporate wrongdoing. The firm is encouraging stockholders who purchased iRhythm securities before January 11, 2022, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis and seeks to recover investor capital and ensure corporate accountability.
Hussman Strategic Advisors Inc. Makes New Investment in iRhythm Technologies $IRTC
Hussman Strategic Advisors Inc. recently acquired 14,700 shares of iRhythm Technologies (NASDAQ:IRTC) in the fourth quarter, a new investment valued at approximately $2.61 million. This comes after iRhythm exceeded Q1 revenue and EPS estimates, reporting $199.4 million in revenue (up 25.6% YoY) and an EPS of -$0.35, and issued FY2026 revenue guidance of $875-$885 million. Despite mixed analyst reactions and significant insider selling, the stock maintains a "Moderate Buy" consensus rating with an average price target of $197.77.
iRhythm Technologies Q1 2026 Results Beat Revenue Expectations, Raise Full-Year Guidance
iRhythm Technologies (IRTC) exceeded revenue expectations in Q1 2026, with sales surging 25.7% to $199.4 million and adjusted EBITDA significantly beating estimates at $14.1 million. The medical technology firm also modestly raised its full-year revenue guidance to $880 million, citing strong demand for its cardiac monitoring devices, operational efficiencies, and strategic investments in AI and new product development, including expansion into sleep diagnostics. The company also addressed regulatory concerns, completing a review of its quality management system following an FDA warning.
Structural Subordination Risk Looms Over iRhythm Holding Company’s Ability to Service 2029 Notes
iRhythm Technologies (IRTC) has disclosed a new risk concerning its holding company's ability to service obligations, specifically guarantees of its 2029 Notes. This structural subordination risk arises because the holding company's cash flow is entirely dependent on its subsidiaries, which have no obligation to provide dividends or loans, and such transfers may be restricted. Despite this, Wall Street analysts maintain a Strong Buy consensus rating on IRTC stock.
iRhythm Technologies (NASDAQ:IRTC) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded iRhythm Technologies (NASDAQ:IRTC) from a "hold" to a "buy" rating following the company's strong Q1 results, which exceeded revenue and EPS expectations. Despite this positive change, the stock faces mixed signals from other analysts, with some issuing price target cuts, and insider selling has also been reported. The company's revenue guidance for FY2026 is in line with consensus, suggesting steady growth but not a significant bullish catalyst.
Oppenheimer Adjusts Price Target on IRhythm Technologies to $185 From $225, Maintains Outperform Rating
Oppenheimer has lowered its price target for IRhythm Technologies (IRTC) from $225 to $185. Despite the reduction in price target, the firm has decided to maintain its Outperform rating for the company.
Irhythm Technologies (IRTC) Receives a Buy from Wells Fargo
Wells Fargo maintained a Buy rating on Irhythm Technologies (IRTC) with a price target of $180.00. This follows BTIG also maintaining a Buy rating with a $185.00 price target. The company reported strong quarterly revenue and net profit, though corporate insider sentiment appears negative due to increased selling of shares.
Canaccord Genuity Group Issues Pessimistic Forecast for iRhythm Technologies (NASDAQ:IRTC) Stock Price
Canaccord Genuity Group has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) from $198.00 to $180.00, while maintaining a "buy" rating. Several other analysts have also reduced their price targets for IRTC. Despite Q1 revenue exceeding expectations by 25.6% year-over-year, the company remains unprofitable, and insider selling has been noted.
iRhythm posts Q1 beats, ups guidance with next-gen Zio algorithm coming
iRhythm (Nasdaq:IRTC) reported better-than-expected first-quarter 2026 financial results, with losses of 43¢ per share on sales of $199.4 million, surpassing Wall Street expectations. The company raised its full-year revenue guidance to between $875 million and $885 million, and adjusted EBITDA margin to 12% to 13%. This positive outlook is further bolstered by anticipated future growth drivers including the next-generation Zio MCT mobile cardiac telemetry platform and a new algorithm, which analysts believe will help sustain and accelerate market share gains.
Oppenheimer Adjusts Price Target on iRhythm Technologies to $185 From $225, Maintains Outperform Rating
Oppenheimer has revised its price target for iRhythm Technologies (NASDAQ: IRTC) downward to $185 from $225 but has maintained an "Outperform" rating on the stock. This adjustment comes despite the company's recent Q1 2026 earnings report, which showed a narrower adjusted loss and increased revenue compared to analyst estimates, with a revenue forecast of $875-$885 million for the year.
iRhythm Technologies, Inc. (NASDAQ:IRTC) Q1 2026 Earnings Call Transcript
iRhythm Technologies, Inc. (IRTC) reported strong Q1 2026 results, exceeding revenue and earnings expectations, with revenue growing 26% year-over-year and adjusted EBITDA margin improving by 880 basis points. The company highlighted growth across its ZioMonitor and Zio AT platforms, expansion in primary care and international markets, and strategic progress in AI-enabled diagnostics and workflow integration. IRTC raised its full-year 2026 revenue guidance to $875 million to $885 million and adjusted EBITDA margin guidance to 12% to 13%, driven by continued volume demand and operational efficiencies.
Wolfe Research lowers iRhythm stock price target on valuation By Investing.com
Wolfe Research has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) to $180 from $200, while maintaining an Outperform rating. The firm based its new target on a discounted cash flow analysis, noting that despite iRhythm's premium growth compared to peers, its enterprise value-to-revenue ratio suggests a more conservative valuation. This adjustment comes after iRhythm reported strong first-quarter 2026 earnings, exceeding analyst expectations for both EPS and revenue.
Truist Cuts PT on iRhythm Technologies (IRTC) as Part of Fiscal Q1 Results Preview in MedTech
Truist and BTIG recently cut their price targets on iRhythm Technologies (IRTC) but reaffirmed Buy ratings, anticipating inline or better Q1 results and strong future revenue growth. The company, a digital healthcare provider specializing in ambulatory cardiac monitoring, is positioned for re-accelerating revenue growth with potential Mobile Cardiac Telemetry service approval. Despite the adjustments, analysts see long-term potential in IRTC.
Truist Cuts PT on iRhythm Technologies (IRTC) as Part of Fiscal Q1 Results Preview in MedTech
Truist has lowered its price target for iRhythm Technologies (IRTC) to $170 from $200, while maintaining a Buy rating. This adjustment is part of a broader preview for fiscal Q1 MedTech results, with the firm anticipating performances to meet or exceed investor expectations. BTIG also cut its price target to $185 from $215, citing a similar broader medical technology review.
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into iRhythm Technologies, Inc. (IRTC) for potential corporate wrongdoing. The firm is encouraging stockholders who purchased iRhythm securities before January 11, 2022, and still hold them, to contact their firm to assist with the investigation. The investigation focuses on whether iRhythm and its officers/directors engaged in illicit actions, and the firm operates on a contingency fee basis for investors.
iRhythm Q1 2026 slides: 25.7% revenue growth, guidance raised
iRhythm Technologies (NASDAQ:IRTC) reported strong Q1 2026 results, exceeding analyst expectations with 25.7% year-over-year revenue growth to $199.4 million and significantly narrowing its net loss. The company raised its full-year 2026 revenue and adjusted EBITDA margin guidance, driven by expansion in the primary care channel, international markets, and anticipated launch of a next-generation MCT device. Despite ongoing GAAP unprofitability and a year-to-date stock decline, iRhythm maintains a dominant market position and solid liquidity.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by iRhythm Technologies, Inc. (NASDAQ:IRTC). The firm encourages iRhythm stockholders who purchased securities before January 11, 2022, and still hold them, to learn more about the investigation. This investigation aims to restore investor capital and ensure corporate accountability.
IRhythm Holdings to Present at the Bank of America Securities 2026 Health Care Conference
IRhythm Holdings, Inc. (NASDAQ: IRTC), a digital healthcare company, announced its participation in the Bank of America Securities 2026 Health Care Conference. Management will present on May 13, 2026, at 9:20 a.m. Pacific Time / 12:20 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the company's investor website.
M&T Bank Corp Takes $3.93 Million Position in iRhythm Technologies $IRTC
M&T Bank Corp has acquired a new stake of 22,168 shares in iRhythm Technologies (NASDAQ:IRTC) during the fourth quarter, valuing their position at approximately $3.93 million. Despite iRhythm beating Q4 earnings expectations with $0.29 EPS against a $0.02 estimate and 27.1% year-over-year revenue growth, the company still faces negative net margins and return on equity. Analysts have a "Moderate Buy" consensus rating for IRTC with an average price target of $202.92, even as company insiders have sold a significant number of shares recently.
Why iRhythm (IRTC) Stock Is Up Today
iRhythm Technologies (IRTC) stock rose 3.4% after presenting positive results from two studies at a heart monitoring conference. The studies demonstrated that iRhythm's 14-day heart monitoring technology is more effective at detecting arrhythmias than traditional 48-hour monitors, especially in patients who had a previous heart procedure and pregnant patients. Despite a 27.7% year-to-date decline, the company has shown strong growth, with revenue increasing by 26.1% year-over-year in Q2 and raised full-year 2025 revenue guidance.
iRhythm data backs long-term ECG in post-ablation, pregnant populations
iRhythm announced new real-world data supporting its Zio long-term heart monitoring technology for post-ablation and pregnant patient populations. The studies presented at HRS 2026 demonstrated that continuous monitoring for up to 14 days detected arrhythmias that would have been missed by shorter monitoring periods, including 30% recurrent AFib in post-ablation patients and 60% of arrhythmias in pregnant patients. These findings emphasize the importance of extended monitoring duration for accurate clinical assessment and decision-making in these patient groups.
Two-day heart monitoring missed 26% of AF returns after ablation
iRhythm Technologies (NASDAQ: IRTC) presented new data at HRS 2026 demonstrating that short-duration 24-48 hour Holter monitoring significantly misses atrial fibrillation (AF) recurrences post-ablation and clinically significant arrhythmias during pregnancy compared to up to 14 days of continuous Zio ambulatory ECG monitoring. The studies showed that 26% of post-ablation AF recurrences and most clinically significant arrhythmias in pregnant patients were detected after 48 hours, highlighting the limitations of shorter monitoring periods and the clinical value of iRhythm's extended monitoring solutions. These findings have implications for clinical practice, including anticoagulation decisions, and reinforce iRhythm's evidence-based differentiation in the market.
iRhythm study shows 14-day monitoring detects more arrhythmias
A new study by iRhythm Holdings (NASDAQ:IRTC) presented at the Heart Rhythm Society’s annual meeting indicates that extended 14-day cardiac monitoring significantly improves the detection of arrhythmias compared to shorter-duration devices. The results from two retrospective analyses, focusing on post-ablation and pregnant patient populations, showed that a substantial percentage of arrhythmias, including clinically significant ones, were detected after the initial 48 hours of monitoring. This suggests that longer monitoring durations, such as those offered by iRhythm's Zio devices, are crucial for comprehensive arrhythmia detection.
Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims on behalf of investors who purchased iRhythm Technologies, Inc. (IRTC) securities before January 11, 2022, and continue to hold them. The investigation focuses on whether iRhythm and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them to assist with the investigation, noting that they represent investors on a contingency fee basis.
iRhythm Technologies (NASDAQ:IRTC) Rating Lowered to Hold at Wall Street Zen
Wall Street Zen has downgraded iRhythm Technologies (NASDAQ:IRTC) from a "buy" to a "hold" rating, despite the company beating quarterly EPS and revenue expectations. The stock, currently trading around $122, has an average "Moderate Buy" rating from analysts with an average price target of $202.92, though several firms have recently lowered their targets. Insider selling of approximately $12.7 million in shares has also been noted in the past 90 days.
iRhythm Technologies (IRTC) Proxy filing Summary
iRhythm Technologies (IRTC) has scheduled its annual meeting for May 27, 2026, where stockholders will vote on the election of nine directors, approval of the 2026 Equity Incentive Plan, amendments to the certificate of incorporation, and the ratification of KPMG LLP as the new independent auditor. The company reported significant growth in 2025 with a 26.2% year-over-year revenue increase to $747.1 million and achieved its first-ever positive free cash flow. The board emphasizes strong corporate governance with 89% independent directors and a focus on diversity and expertise.
iRhythm Technologies (IRTC) to Release Earnings on Thursday
iRhythm Technologies (IRTC) is scheduled to release its Q1 2026 earnings after market close on Thursday, April 30th. Analysts anticipate a loss of ($0.664) per share on revenues of $194.1 million. The company's stock currently trades around $121.95, with a market cap of $3.94 billion and a consensus analyst price target of $202.92, indicating a "Moderate Buy" rating.
iRhythm Technologies (IRTC) Q2 2024 earnings summary
iRhythm Technologies reported strong Q2 2024 results with revenue up 19.3% year-over-year to $148.0 million, driven by demand for its Zio product and expansion into new markets. The company raised its full-year 2024 revenue guidance to $580-$590 million and improved its outlook for gross margin and adjusted EBITDA margin. IRTC also addressed an FDA warning letter and announced a CFO transition.
